Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Paediatric Joint Formulary
Home > Formulary : Paediatric > Recent Decisions > 2021 >

Decisions 14th December 2021

At the meeting on the 14th December, the following decisions were agreed


New Drug Requests 


Guanfacine (TLS Red) 

  • For treatment of ADHD in children and adolescents aged 6-17 years, where stimulants are not suitable, not tolerated or ineffective as a joint 3rd line option with atomoxetine.

Hydrocortisone (Alkindi) (TLS Amber No SCP) 

  • For adrenal insufficiency in children from birth to <6 years old in whom oral feeding is established and require less than 5mg dose.

Hydrocortisone (Efmody) (TLS Amber No SCP) 

  • For congenital adrenal hyperplasia in children who are not adequately controlled or have experienced androgen excess with immediate release hydrocortisone.  Long-term use of Efmody permitted only if long-term benefit on hormone profile has been demonstrated. 


Other Formulary Decisions

Trurapi® (Insulin Aspart) to be added to the BNSSG Paediatric Formulary as TLS Green for new patients only to mirror the indication on the Adult Formulary. 


Further Work

Guanfacine for ADHD in children and adolescents aged 6-17 years to be included on the BNSSG Paediatric Joint Formulary as TLS Amber 3 months once a shared care protocol has been developed and approved. To be included as TLS Red in the interim. 

Cefazolin for treatment of susceptible MSSA infections where flucloxacillin is not suitable due to intolerance or adverse effects to be included on the Formulary as TLS Red, restricted to use on microbiology advice only once directorate sign-off is confirmed. 

Dapsone tablets - for treatment of dermatoses and oral ulceration.  Further information required for Joint Formulary Group to assess application.